TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at human S1P2 in HFL1 cells assessed as inhibition of EC80 S1P-induced IL8 release incubated for 16 to 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Antagonist activity at CCR2 expressed in THP1 cells assessed as MCP1-induced calcium fluxMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMAssay Description:Antagonist activity at human S1P2 in HFL1 cells assessed as inhibition of EC80 S1P-induced IL8 release incubated for 16 to 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.5nMAssay Description:Inhibition of human CCR2More data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
Affinity DataIC50: 3.40nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
Affinity DataIC50: 3.5nMAssay Description:Antagonist activity at human S1P2 in HFL1 cells assessed as inhibition of EC80 S1P-induced IL8 release incubated for 16 to 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 3.5nMAssay Description:Antagonist activity at CCR2 receptor expressed in THP1 cells assessed as MCP-1-induced calcium flux by chemotoxis assayMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human CCR2More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human CCR2More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Antagonist activity at human CCR2More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human CCR2More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human CCR2More data for this Ligand-Target Pair
Affinity DataIC50: 4.80nMAssay Description:Antagonist activity at human S1P2 in HFL1 cells assessed as inhibition of EC80 S1P-induced IL8 release incubated for 16 to 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Antagonist activity at human S1P2 in HFL1 cells assessed as inhibition of EC80 S1P-induced IL8 release incubated for 16 to 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of human CCR2More data for this Ligand-Target Pair
Affinity DataIC50: 5.60nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
Affinity DataIC50: 5.60nMAssay Description:Antagonist activity at human S1P2 in HFL1 cells assessed as inhibition of EC80 S1P-induced IL8 release incubated for 16 to 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Antagonist activity at human CCR2More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Antagonist activity at human CCR2More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6.30nMAssay Description:Inhibition of human CCR2More data for this Ligand-Target Pair
Affinity DataIC50: 6.60nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Antagonist activity at human CCR2More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 7.60nMAssay Description:Antagonist activity at human S1P2 in HFL1 cells assessed as inhibition of EC80 S1P-induced IL8 release incubated for 16 to 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 7.70nMAssay Description:Inhibition of human CCR2More data for this Ligand-Target Pair
Affinity DataIC50: 7.70nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
Affinity DataIC50: 7.70nMAssay Description:Antagonist activity against human S1P2 assessed as inhibition of beta-arrestin 2 recruitmentMore data for this Ligand-Target Pair
Affinity DataIC50: 8.10nMAssay Description:Antagonist activity at human S1P2 in HFL1 cells assessed as inhibition of EC80 S1P-induced IL8 release incubated for 16 to 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataIC50: 8.80nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Antagonist activity at human S1P2 receptor expressed in CHO cells assessed as inhibition of calcium fluxMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Binding affinity at human CCR2 receptorMore data for this Ligand-Target Pair
TargetProstaglandin G/H synthase 1/2(RAT)
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
The R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibitory activity against Cyclooxygenase (COX) using broken rat barophilic leukemia cells (RBL-1)More data for this Ligand-Target Pair